DMTRF (3-D Matrix) 3-Year RORE % : -133.93% (As of Jan. 2026)


DMTRF 3-D Matrix Ltd DMTRF
57 GF Score
Price $2.25
GF Value $2.15
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is 3-D Matrix 3-Year RORE %?

3-D Matrix DMTRF 57 3-Year RORE % is -133.93 as of Jan. 2026. GuruFocus rates DMTRF with a GF Score™ of 57/100 and a GF Value™ of $2.15 (Fairly Valued). The stock has 3 warning signs investors should review. Among 782 Medical Devices & Instruments companies, 3-D Matrix ranks worse than 94.12% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. 3-D Matrix's 3-Year RORE % for the quarter that ended in Jan. 2026 was -133.93%.

The industry rank for 3-D Matrix's 3-Year RORE % or its related term are showing as below:

DMTRF's 3-Year RORE % is ranked worse than
94.12% of 782 companies
in the Medical Devices & Instruments industry
Industry Median: -4.31 vs DMTRF: -133.93

3-D Matrix  (OTCPK:DMTRF) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


3-D Matrix 3-Year RORE % Related Terms


3-D Matrix 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for 3-D Matrix's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

3-D Matrix 3-Year RORE % Chart

3-D Matrix Annual Data
Trend Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25 Apr26
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -34.41 -13.83 -45.44 -32.13 0.00

3-D Matrix Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -32.13 -114.14 -70.39 -133.93 0.00

DMTRF vs ABT, SYK, MDT: 3-Year RORE % Comparison

For the Medical Devices subindustry, 3-D Matrix's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


3-D Matrix 3-Year RORE % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, 3-D Matrix's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where 3-D Matrix's 3-Year RORE % falls into.


DMTRF
57GF Score
3-D Matrix Ltd DMTRF
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

3-D Matrix 3-Year RORE % Calculation

3-D Matrix's 3-Year RORE % for the quarter that ended in Jan. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( 0.225--0.032 )/( 0.04-0 )
=0.257/0.04
=642.50 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jan. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -133.93 mean?
3-D Matrix (DMTRF) has a 3-Year RORE % of -133.93 as of Jan. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on 3-D Matrix and its competitors. According to the industry distribution chart, 3-D Matrix ranks #736 out of 782 companies in the Medical Devices & Instruments industry, placing it in the top 94.1%.
Is 3-D Matrix's 3-Year RORE % too high?
3-D Matrix's current 3-Year RORE % is -133.93. Based on the distribution chart, 3-D Matrix ranks #736 out of 782 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, 3-D Matrix has a GF Score™ of 57/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does 3-D Matrix's 3-Year RORE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, 3-D Matrix ranks #736 out of 782 companies for 3-Year RORE %. This places 3-D Matrix in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on 3-D Matrix and its competitors. 3-D Matrix's current 3-Year RORE % is -133.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3-D Matrix stock overvalued right now?
Based on GuruFocus' analysis, 3-D Matrix (DMTRF) is currently considered Fairly Valued. The stock's GF Value™ is $2.15, compared to a current price of $2.25 — trading 4.7% above its estimated fair value. The current 3-Year RORE % is -133.93. 3-D Matrix's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For 3-D Matrix (DMTRF), the current 3-Year RORE % is -133.93 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 3-D Matrix (DMTRF) Overvalued in 2026?

Based on GuruFocus' analysis, 3-D Matrix stock appears to be overvalued. The current stock price of $2.25 is trading 4.7% above its estimated GF Value™ of $2.15. GuruFocus considers 3-D Matrix to be Fairly Valued.

Key valuation signals for DMTRF:

  • 3-Year RORE %: -133.93
  • GF Value™: $2.15 vs. price of $2.25 (4.7% above fair value)
  • GF Score™: 57/100 with 3 warning signs

No single metric tells the full story. See the DMTRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


3-D Matrix Business Description

Other Exchanges 7777:Japan
Address 3-2-4 Kojimachi, Chiyoda-ku, 7th floor, Kojimachi HF Building, Tokyo, JPN, 102-0083
3-D Matrix Ltd is engaged in the research, development, manufacture, and sale of medical devices based on the self-assembling peptide technology. Its products include PuraMatrix, High Concentration PuraMatrix, Modified Peptide and GMP Grade PuraMatrix.
57GF Score

Get the complete analysis for DMTRF

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.25
Price
$2.15
GF Value